TRi-1 manufacturers
- TRi-1
-
- $67.00
-
2026-07-27
- CAS:246020-68-8
- Purity: 98.40%
- Supply Ability: 10g
- TRi-1
-
-
2026-07-15
- CAS:246020-68-8
- Min. Order: 1KG
- Purity: 98%
- Supply Ability: 1000kg
|
| Product Name: | TRi-1 | | Synonyms: | TRi-1;TRi-1(TXNRD1 inhibitor 1);antitumor,inhibit,TRi 1,Inhibitor,FaDu,thioredoxin reductase 1,glutathione,TRi-1,TRi1,TXNRD1;Pyridine, 2-[(4-chlorophenyl)sulfonyl]-6-methoxy-3-nitro-;TRi-1, 10 mM in DMSO | | CAS: | 246020-68-8 | | MF: | C12H9ClN2O5S | | MW: | 328.73 | | EINECS: | | | Product Categories: | | | Mol File: | 246020-68-8.mol |  |
| | TRi-1 Chemical Properties |
| Boiling point | 533.2±50.0 °C(Predicted) | | density | 1.502±0.06 g/cm3(Predicted) | | storage temp. | 4°C, protect from light | | solubility | DMSO : 62.5 mg/mL (190.13 mM; Need ultrasonic) | | form | Solid | | pka | -8.51±0.29(Predicted) | | color | Light yellow to yellow |
| | TRi-1 Usage And Synthesis |
| Uses | TRi-1 is a potent, specific and irreversible inhibitor of cytosolic thioredoxin reductase 1 (TXNRD1), with an IC50 of 12 nM. TRi-1 has little mitochondrial toxicity for anticancer therapy[1]. | | in vivo | TRi-1 (10 mg/kg; i.v.; twice a day for 4 days or 5 mg/kg; i.p.; twice a week for 3 weeks) impaires growth and viability of human tumor xenografts and syngeneic mouse tumors[1]. | Animal Model: | SCID mice bearing established human FaDu cell xenografts[1] | | Dosage: | 10 mg/kg | | Administration: | Intravenous injection, twice a day for 4 days | | Result: | Resulted in decreased tumor growth compared to vehicle controls within four days with no signs of overt toxicity or changes in mouse weight relative to vehicle control.
|
| Animal Model: | PyMT-MMTV mice that spontaneously develop malignant breast cancer tumors[1] | | Dosage: | 5 mg/kg | | Administration: | Intraperitoneal injection, twice a week for 3 weeks | | Result: | Impaired tumor growth, significantly reduced tumor volumes. |
| | References | [1] Stafford WC, et al. Irreversible inhibition of cytosolic thioredoxin reductase 1 as a mechanistic basis for anticancer therapy. Sci Transl Med. 2018 Feb 14;10(428). pii: eaaf7444. DOI:10.1126/scitranslmed.aaf7444 |
| | TRi-1 Preparation Products And Raw materials |
|